Drug intelligence / Profile preview

gypenoside L

Development stage
Preclinical
Lead developer
Fujian Medical University
Modality
Small Molecules
Administration
Oral
01

Overview

Gypenoside L is a dammarane-type saponin isolated from the herbaceous vine *Gynostemma pentaphyllum* (Jiaogulan). It has been investigated for its anti-proliferative and anti-tumor properties, particularly in preclinical models of human liver and esophageal cancer. The compound acts by inducing cellular senescence and S-phase cell cycle arrest, rather than immediate apoptosis. This effect is mediated through the activation of the p38 and ERK mitogen-activated protein kinase (MAPK) pathways, as well as the NF-κB signaling pathway, which subsequently upregulates the senescence-related cyclin-dependent kinase inhibitors p21 and p27. Preclinical studies also suggest that gypenoside L can act as a chemosensitizer, enhancing the cytotoxicity of standard chemotherapeutic agents such as 5-fluorouracil and cisplatin.

Other names
Gyp-L
02

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)NF-κBCDKN1B (Transmembrane emp24 domain-containing protein 7)MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on gypenoside L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gypenoside L.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call